ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
InterMune Announces Approval Of Clinical Trial Authorization For Phase 1b Trial Of ITMN-191
InterMune, Inc.
(Nasdaq: ITMN) announced that the amended Clinical Trial
Authorization (CTA) related to the Phase 1b clinical trial of ITMN-191
(Roche-R7227) has been approved by the appropriate European regulatory
authorities. InterMune also has received approval from the Ethics Committee
of the institutions that will conduct the Phase 1b study. ITMN-191 is an
orally available hepatitis C virus (HCV) protease inhibitor in development
by InterMune and its partner, Roche.
InterMune expects that the Phase 1b multiple ascending dose (MAD) study
will begin this month and expects to announce initial top-line viral
kinetic and safety results from the first three dose cohorts of the MAD
study in the first quarter of 2008.
Dan Welch, President and Chief Executive Officer of InterMune, said,
"InterMune and Roche are pleased to announce that we have successfully
secured the required regulatory approvals that enable us to initiate our
very important Phase 1b multiple ascending dose study. By amending the
Phase 1b protocol, we believe we have enhanced our ability to deliver the
most robust Phase 1b results possible which we expect will place us in a
stronger position to begin our Phase 2 trials."
In early May, InterMune announced that it would amend the CTA to take
into consideration new information on competitive protease inhibitors,
in-vitro and preclinical data on ITMN-191 and pharmacokinetic observations
from a Phase 1a study that was completed in May of 2007. In that study, a
higher than anticipated exposure of ITMN-191 in plasma was observed in
subjects dosed with food, suggesting that ITMN-191 may be administered in
subsequent clinical studies at lower doses than were previously estimated.
The Phase 1b study is designed to assess the effect on viral kinetics,
viral resistance, pharmacokinetics, safety and tolerability of multiple
ascending doses of ITMN-191 given as a monotherapy. InterMune plans to
administer ITMN-191 for a period of 14 days to three ascending dose cohorts
of treatment-naive chronic hepatitis C patients infected with HCV genotype
1. Twice per day (BID) and three-times per day (TID) dose regimens will be
studied. In addition, a single cohort of non-responder patients will be
studied. If results of the first three dose cohorts indicate that more
information would be desirable to fully inform the Phase 2 program, the
Phase 1b study will be expanded to additional cohorts.
About InterMune
InterMune is a biotechnology company focused on the research,
development and commercialization of innovative therapies in pulmonology
and hepatology. InterMune has a pipeline portfolio addressing idiopathic
pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The
pulmonology portfolio includes the Phase 3 program, CAPACITY, which is
evaluating pirfenidone as a possible therapeutic candidate for the
treatment of patients with IPF and a research program focused on small
molecules for pulmonary disease. The hepatology portfolio includes the HCV
protease inhibitor compound ITMN-191 (referred to as R7227 within the Roche
research and development programs) in Phase 1a, a second-generation HCV
protease inhibitor research program, and a research program evaluating a
new target in hepatology. For additional information about InterMune and
its R&D pipeline, please visit http://www.intermune.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of section 21E of the Securities Exchange Act of 1934, as amended,
that reflect InterMune's judgment and involve risks and uncertainties as of
the date of this release, including without limitation the statements
related to anticipated product development timelines. All forward-looking
statements and other information included in this press release are based
on information available to InterMune as of the date hereof, and InterMune
assumes no obligation to update any such forward-looking statements or
information. InterMune's actual results could differ materially from those
described in InterMune's forward-looking statements.
Factors that could cause or contribute to such differences include, but
are not limited to, those discussed in detail under the heading "Risk
Factors" in InterMune's most recent annual report on Form 10-K filed with
the SEC on March 30, 2007 (the "Form 10-K") and other periodic reports
filed with the SEC, including the following: (i) risks related to the long,
expensive and uncertain clinical development and regulatory process,
including having no unexpected safety, toxicology, clinical or other issues
or delays in anticipated timing of the regulatory approval process; (ii)
risks related to failure to achieve the clinical trial results required to
commercialize our product candidates; and (iii) risks related to timely
patient enrollment and retention in clinical trials. The risks and other
factors discussed above should be considered only in connection with the
fully discussed risks and other factors discussed in detail in the Form
10-K and InterMune's other periodic reports filed with the SEC, all of
which are available via InterMune's web site at http://www.intermune.com.
InterMune, Inc.
http://www.intermune.com
InterMune Announces Aprobarea studiului clinic autorizaþia pentru Faza 1b proces al ITMN-191 - InterMune Announces Approval Of Clinical Trial Authorization For Phase 1b Trial Of ITMN-191 - articole medicale engleza - startsanatate